DCBs, CLTI & complex aorta: new trial data

In this PVI 2025 session replay dedicated to late-breaking trials, several major studies provide fresh insights across peripheral and aortic interventions. 

Three-year results from the LUMIFOLLOW registry confirm the sustained safety and efficacy of the Luminor drug-coated balloon (DCB) in femoropopliteal lesions, with durable quality-of-life benefits in a broad, real-world population, including complex and high-risk cases. 

New data from the DEEPER REVEAL trial highlight the performance of a retrievable stent system in CLTI, demonstrating high acute success rates and meaningful clinical benefit at six months, supported by recent FDA clearance. 

The session also covers advances in transcatheter arterialisation of deep veins with PROMISE III, as well as first-in-human results from the BRight DCB study, underscoring the importance of drug specificity and challenging the notion of a uniform “class effect” among DCBs.

Finally, early findings from the European Aortic Data Collection (EADC) registry point to promising safety outcomes in complex aortic aneurysm repair, reinforcing the value of prospective real-world data in refining endovascular strategies.

From femoropopliteal disease to complex aortic repair, catch the trials shaping tomorrow’s practice!